|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 内侧固定平台单髁置换术后的冠状面下肢力线是翻修的影响因素显示文摘膝关节单髁置换术(unicompartmental knee arthroplasty,UKA)后患者冠状面的下肢力线被认为是影响手术长期疗效的一个重要因素,但关于最佳的UKA术后下肢力线还没有形成明确共识。一些研究主张术后下肢力线应保持在中立位,而另一些研究认为即使术后下肢力线存在10°的内翻也可获得良好的临床效果。 | Sean E Slaven John P Cody Robert A Sershon Henry Ho Robert H Hopper Jr Kevin B Fricka 李亚坤(整理) 张民(整理) | 2020 | 实用骨科杂志2020，26，12： | 15 |
| 2 | Cystic lymphangioma of the pancreas显示文摘Lymphangioma of the pancreas is an extremely rare benign tumour of lymphatic origin,with fewer than 60 published cases. Histologically,it is polycystic,with the cysts separated by thin septa and lined with endothelial cells. Though congenital,it can affect all age groups,and occurs more frequently in females. Patients usually present with epigastric pain and an associated palpable mass. Complete excision is curative,even though,depending on the tumour location,surgery may be simple or involve extensive pancreatic resection and anastomoses. The authors present a 49-year-old woman in whom a polycystic septated mass,35 mm x 35 mm in size,was discovered by ultrasonography (US) in the body of the pancreas during investigations for epigastric pain and nausea. At surgery,a well circumscribed polycystic tumor was completely excised,with preservation of the pancreatic duct. The postoperative recovery was uneventful. Histology confirmed a microcystic lymphangioma of the pancreas. Immunohistochemistry showed cystic endothelial cells reactivity to factor Ⅷ -RA (++),CD31 (+++) and CD34 (-). Postoperatively,abdominal pain disappeared and the patient remained symptomfree for 12 mo until now. Although extremely rare,lymphangioma of the pancreas should be taken into consideration as a differential diagnosis of a pancreatic cystic lesion,especially in women. | Radoje B Colovic Nikica M Grubor Marjan T Micev Henry Dushan E Atkinson Vitomir I Rankovic Mihajlo M Jagodic | 2008 | World Journal of Gastroenterology2008，14，44： | 6 |
| 3 | Patient satisfaction and penile morphology changes with postoperative penile rehabilitation 2 years after Coloplast Titan prosthesis显示文摘在可膨胀的阴茎修复术外科以后的普通抱怨被减少阴茎长度。我们以前报导了用有好攻击的新长度测量的 Coloplast 泰坦可膨胀的阴茎修复术,技术(NLMT ) 怎么结合了 implant 的手术后的 IPP 康复为 1 年帮助改进耐心的满足和可勃起的阴茎大小。这是 2 年后续一未来,三中心,经历了泰坦修复术放置的 40 个病人的学习,与为可勃起的机能障碍的新长度测量技术。耐心的指令是每天使膨胀 6 个月然后每天为 1-2 h 最大地使膨胀 6-24 月。十五阴茎大小以前并且立即在外科以后并且在后续访问被拿。测量变化作为与相比在 24 个月被改进立即手术后并且在 12 个月。67.8% 题目在 2 年对他们的长度满意,并且 77% 作为在外科以前察觉了更长的阴茎长度(30.8%) 或一样(46.2%) 。64.3% 题目和 17.9% 增加了并且未改变的满足,分别地与阴茎长度作为与相比在以前阴茎植入外科。几乎,一个题目(96.5%) 对他的全面功能满意植入。这研究与好攻击的柱体缩放,和手术后的阴茎康复通货膨胀用 Coloplast 泰坦建议协议能在 2 年 postimplant 优化耐心的满足和可勃起的阴茎大小。 | Michael B Pryor Rafael Carrion Run Wang Gerard Henry | 2016 | Asian Journal of Andrology2016，18，5： | 5 |
| 4 | TG13 flowchart for the management of acute cholangitis and cholecystitis显示文摘 | Fumihiko Miura Tadahiro Takada Steven M. Strasberg Joseph S. Solomkin Henry A. Pitt Dirk J. Gouma O. James Garden Markus W. Büchler Masahiro Yoshida Toshihiko Mayumi Kohji Okamoto Harumi Gomi Shinya Kusachi Seiki Kiriyama Masamichi Yokoe Yasutoshi Kimura | 2013 | Journal of Hepato-Biliary-Pancreatic Sciences2013，，1： | 4 |
| 5 | Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements显示文摘Vector-borne protozoan diseases represent a serious public health challenge,especially in the tropics where poverty together with vector-favorable climates are the aggravating factors.Each of the various strategies currently employed to face these scourges is seriously inadequate.Despite enormous efforts,vaccines-which represent the ideal weapon against these parasitic diseases—are yet to be sufficiently developed and implemented.Chemotherapy and vector control are therefore the sole effective attempts to minimize the disease burden.Nowadays,both strategies are also highly challenged by the phenomenon of drug and insecticide resistance,which affects virtually all interventions currently used.The recently growing support from international organizations and governments of some endemic countries is warmly welcome,and should be optimally exploited in the various approaches to drug and insecticide research and development to overcome the burden of these prevalent diseases,especially malaria,leishmaniasis,Human African Trypanosomiasis(HAT),and Chagas disease. | Denis Zofou Raymond B Nyasa Dickson S Nsagha Fidele Ntie-Kang Henry D Meriki Jules Clement N Assob Victor Kuete | 2014 | Infectious Diseases of Poverty2014，3，1： | 4 |
| 6 | rate of adverse events of gastroduodenal snare polypectomy for non-flat polyp is low: A prospective and multicenter study显示文摘AIM To evaluate the rate of adverse events(AEs) during consecutive gastric and duodenal polypectomies in several Spanish centers. METHODS Polypectomies of protruded gastric or duodenal polyps ≥ 5 mm using hot snare were prospectively included. Prophylactic measures of hemorrhage were allowed in predefined cases. AEs were defined and graded according to the lexicon recommended by the American Society for Gastrointestinal Endoscopy. Patients were followed for 48 h, one week and 1 mo after theprocedure. RESULTS308 patients were included and a single polypectomy was performed in 205. Only 36(11.7%) were on prior anticoagulant therapy. Mean polyp size was 15 ± 8.9 mm(5-60) and in 294 cases(95.4%) were located in the stomach. Hemorrhage prophylaxis was performed in 219(71.1%) patients. Nine patients presented AEs(2.9%), and 6 of them were bleeding(n = 6, 1.9%)(in 5 out of 6 AE, different types of endoscopic treatment were performed). Other 24 hemorrhagic episodes could be managed without any change in the outcome of the endoscopy and, consequently, were considered incidents. We did not find any independent risk factor of bleeding.CONCLUSION Gastroduodenal polypectomy using prophylactic measures has a rate of AEs small enough to consider this procedure a safe and effective method for polyp resection independently of the polyp size and location. | Henry Córdova Lidia Argüello Carme Loras Antonio Naranjo Rodríguez Faust Riu Pons Joan B Gornals David Nicolás-Pérez Xavier Andújar Murcia Luis Hernández Santos Santolaria Carles Leal Carles Pons Enrique Pérez-Cuadrado-Robles Orlando García-Bosch Michel Papo Berger José Luis Ulla Rocha Cristina Sánchez-Montes Gloria Fernández-Esparrach | 2017 | World Journal of Gastroenterology2017，23，47： | 3 |
| 7 | Community epidemiology of Chlamydia and Mycoplasma pneumoniae in LRTI in France over 29 months显示文摘 | Jacques Gaillat Antoine Flahault Bertille Barbeyrac Jeanne Orfila Henri Portier Jean-Pierre Ducroix Christiane Bébéar Charles Mayaud | 2005 | European Journal of Epidemiology2005，，7： | 3 |
| 8 | Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines显示文摘 | Keita Wada Tadahiro Takada Yoshifumi Kawarada Yuji Nimura Fumihiko Miura Masahiro Yoshida Toshihiko Mayumi Steven Strasberg Henry A. Pitt Thomas R. Gadacz Markus W. Büchler Jacques Belghiti Eduardo de Santibanes Dirk J. Gouma Horst Neuhaus Christos Derven | 2007 | Journal of Hepato - Biliary - Pancreatic Surgery2007，，1： | 2 |
| 9 | Perigastric extraskeletal Ewing's sarcoma: A case report显示文摘Ewing's sarcoma (ES) is a neoplasm of undifferentiated small round cells, which occurs in the bones and deep soft tissues of children and adolescents. We present a rare case of a 44-year-old woman with gastric ES presenting with epigastric pain and weight loss. Ultrasound and computed tomography scans indicated a solid/cystic mass in the pancreatic tail. At laparotomy, the tumor was found attached to the posterior surface of the stomach, completely free from the pancreas, with no lymphadenopathy or local metastases. The polynodal, partly pseudocystic, dark-red soft tumor was excised. Histopathology revealed an anaplastic small-round-cell tumor with strong membranous CD99 immunoexpression. Additionally, there was patchy immunostaining for S-100 protein, vimentin, protein gene product (PGP) 9.5 and neuron-specifi c enolase, and weak focal CD117 cytoplasmic immunoreactivity. The patient had no adjuvant chemotherapy; her postoperative recovery was uneventful, and she remains symptom-free, and without any sign of recurrence at 20 mo. To the best of our knowledge, this is only the third ever case of gastric ES. | Radoje B Colovic Nikica M Grubor Marjan T Micev Slavko V Matic Henry Dushan Edward Atkinson Stojan M Latincic | 2009 | World Journal of Gastroenterology2009，15，2： | 2 |
| 10 | CD 64 distinguishes macrophages from dendritic cells in the gut and reveals the T h1‐inducing role of mesenteric lymph node macrophages during colitis显示文摘 | Samira Tamoutounour Sandrine Henri Hugues Lelouard Béatrice de Bovis Colin de Haar C. Janneke van der Woude Andrea M. Woltman Yasmin Reyal Dominique Bonnet Dorine Sichien Calum C. Bain Allan McI. Mowat Caetano Reis e Sousa Lionel F. Poulin Bernard Malisse | 2012 | Eur J Immunol2012，，12： | 2 |
| 11 | Outcomes of submucosal(T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection显示文摘AIM To investigate the outcomes and recurrences of p T1 b esophageal adenocarcinoma(EAC) following endoscopic mucosal resection(EMR) and associated treatments.METHODS Patients undergoing EMR with pathologically confirmed T1 b EAC at two academic referral centers were retrospectively identified.Patients were divided into 4 groups based on treatment following EMR:Endoscopic therapy alone(group A),endoscopic therapy with either chemotherapy,radiation or both(group B),surgicalresection(group C) or no further treatment/lost to follow-up(<12 mo)(group D).Pathology specimens were reviewed by a central pathologist.Follow-up data was obtained from the academic centers,primary care physicians and/or referring physicians.Univariate analysis was performed to identify factors predicting recurrence of EAC.RESULTS Fifty-three patients with T1 b EAC underwent EMR,of which 32(60%) had adequate follow-up ≥ 12 mo(median 34 mo,range 12-103).There were 16 patients in group A,9 in group B,7 in group C and 21 in group D.Median follow-up in groups A to C was 34 mo(range 12-103).Recurrent EAC developed overall in 9 patients(28%) including 6(38%) in group A(median:21 mo,range:6-73),1(11%) in group B(median:30 mo,range:30-30) and 2(29%) in group C(median 21 mo,range:7-35.Six of 9 recurrences were local;of the 6 recurrences,5 were treated with endoscopy alone.No predictors of recurrence of EAC were identified.CONCLUSION Endoscopic therapy of T1 b EAC may be a reasonable strategy for a subset of patients including those either refusing or medically unfit for esophagectomy. | Darren D Ballard Neel Choksi Jingmei Lin Eun-Young Choi B Joseph Elmunzer Henry Appelman Douglas K Rex Hala Fatima William Kessler John M DeWitt | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，20： | 2 |
| 12 | Identification of severe acute respiratory syndrome in Canada显示文摘 | Poutanen SM Low DE Henry B | 2003 | N Engl J Med2003，348，： | 2 |
| 13 | Identification of Severe Acute Respiratory Syndrom in Canda显示文摘 | Poutanen SM Low DE Henry B | 2003 | N Engl J Med2003，10，： | 1 |
| 14 | Identification of severe acute respiratory syndrome in Canada显示文摘 | Poutanen S M Low D E Henry B | 2003 | N Engl J Med2003，348，20： | 1 |
| 15 | A simple and rapid preparation of alditol acetates for monosaccharide analysis显示文摘 | BLAKENEY A B HARRIS P J HENRY R J | 1983 | Carbohydrate Research1983，113，： | 1 |
| 16 | The accuracy and stability of an implicit solution method for the fractional diffusion equation显示文摘 | Langlands T A M Henry B I | 2005 | J Comp Phys2005，205，： | 1 |
| 17 | Identification of severe acute respiratory syndrome in Canada显示文摘 | Poutanen SM Low DE Henry B | | 0，，： | 1 |
| 18 | Albuterol and levalbuterol use and spending in medicare beneficiaries with chronic obstructive pulmonary disease显示文摘 | Andrea P Sean M Henry B | 2010 | Am J Geriat Pharmacother2010，8，6： | 1 |
| 19 | Whole bloodaggregation and coagulation in db/db and ob/ob mouse models of type 2 diabetes显示文摘 | Henry M L Davidson L B Wilson J E | 2008 | Blood Coagul Fibrinolysis2008，19，2： | 1 |
| 20 | Quantitative detection of the nosZ gene, encoding nitrous oxide reductase, and comparison of the abundances of 16S rRNA, narG, nirK, and nosZ genes in soils显示文摘 | Henry S Bru D Stres B | 2006 | Appl Environ Micrab2006，72，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员